Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Position Decreased by Banco Santander S.A.

Banco Santander S.A. trimmed its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 61.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 208,196 shares of the biopharmaceutical company’s stock after selling 332,280 shares during the quarter. Banco Santander S.A. owned approximately 0.13% of Ocular Therapeutix worth $1,895,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Franklin Resources Inc. purchased a new position in Ocular Therapeutix in the 4th quarter worth about $20,071,000. Deltec Asset Management LLC boosted its holdings in shares of Ocular Therapeutix by 18.5% in the fourth quarter. Deltec Asset Management LLC now owns 2,443,607 shares of the biopharmaceutical company’s stock worth $10,898,000 after buying an additional 381,810 shares during the period. Great Point Partners LLC purchased a new position in shares of Ocular Therapeutix in the fourth quarter worth approximately $3,122,000. Artia Global Partners LP acquired a new stake in shares of Ocular Therapeutix during the fourth quarter valued at approximately $1,962,000. Finally, Essex Investment Management Co. LLC lifted its position in shares of Ocular Therapeutix by 1.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 376,200 shares of the biopharmaceutical company’s stock valued at $3,423,000 after acquiring an additional 5,828 shares in the last quarter. 59.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

OCUL has been the topic of several research analyst reports. TD Cowen cut shares of Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 21st. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Ocular Therapeutix in a report on Friday, June 14th. StockNews.com lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. JMP Securities lowered their target price on Ocular Therapeutix from $24.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 8th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Friday, June 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Ocular Therapeutix Stock Up 1.3 %

NASDAQ OCUL traded up $0.10 on Friday, reaching $7.85. The stock had a trading volume of 1,168,758 shares, compared to its average volume of 2,339,293. Ocular Therapeutix, Inc. has a 1 year low of $2.00 and a 1 year high of $11.31. The business has a 50 day moving average price of $6.27 and a 200 day moving average price of $6.71. The company has a current ratio of 21.39, a quick ratio of 21.29 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -5.81 and a beta of 1.30.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The firm had revenue of $14.77 million during the quarter, compared to the consensus estimate of $15.43 million. Ocular Therapeutix had a negative net margin of 192.61% and a negative return on equity of 76.64%. On average, analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.